ecancermedicalscience

ecancermedicalscience is an open access cancer journal focused on under-resourced communities. In order to help reduce global inequalities in cancer care and treatment, we provide free access to all articles from the point of publication and we only charge authors who have specific funding to cover publication costs.

The journal considers articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epidemiology, clinical reports, controlled trials (in particular if they are independent or publicly funded trials), health systems, cancer policy and regulatory aspects of cancer care.

Editor-in-Chief: Dr Eduardo Cazap, MD PhD (President SLACOM)

ISSN: 1754-6605

Submit article

683-innovations-that-reach-the-patient-early-health-technology-assessment-and-improving-the-chances-of-coverage-and-implementation

Special Issue: Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation

WH van Harten, VP Retèl

28 Oct 2016

https://doi.org/10.3332/ecancer.2016.683

Abstract | Full Article | PDF

682-comparison-between-standard-and-reduced-volume-radiotherapy-in-bladder-preservation-trimodality-protocol-for-muscle-invasive-bladder-cancer-patients

Research: Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients

Waleed Arafat, Azza Darwish, George E Naoum, Wael Sameh, Gamal El Husseiny, Fathy Abd-El-Gawad, Mostafa Samir

26 Oct 2016

https://doi.org/10.3332/ecancer.2016.682

Abstract | Full Article | PDF

681-phosphoethanolamine-and-the-danger-of-unproven-drugs

Policy: Phosphoethanolamine and the danger of unproven drugs

Noam Pondé, Evandro de Azambuja, Felipe Ades

17 Oct 2016

https://doi.org/10.3332/ecancer.2016.681

Abstract | Full Article | PDF | Portuguese

680-repurposing-drugs-in-oncology-redo-propranolol-as-an-anti-cancer-agent

Clinical Study: Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme, Lydie Meheus, Ilse Rooman, Vikas P Sukhatme

12 Oct 2016

https://doi.org/10.3332/ecancer.2016.680

Abstract | Full Article | PDF

679-prognostic-and-predictive-implications-of-sokal-euro-and-eutos-scores-in-chronic-myeloid-leukaemia-in-the-imatinib-era-experience-from-a-tertiary-oncology-centre-in-southern-india

Research: Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India

Lakshmaiah Chinnagiriyappa Kuntegowdanahalli, Govind Babu Kanakasetty, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Rajeev Krishnappa Lakkavalli, Lokesh N Kadabur, Rudresha Antapura Haleshappa

6 Oct 2016

https://doi.org/10.3332/ecancer.2016.679

Abstract | Full Article | PDF

678-the-first-case-of-benign-multicystic-mesothelioma-presenting-as-a-splenic-mass

Case Report: The first case of benign multicystic mesothelioma presenting as a splenic mass

Antonio D'Antonio, Carlo Baldi, Maria Addesso, Carmine Napolitano

4 Oct 2016

https://doi.org/10.3332/ecancer.2016.678

Abstract | Full Article | PDF

677-veror-radiotherapy-for-low-burden-cancer-789-patients-with-957-lesions

Research: VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions

R Orecchia, A Surgo, M Muto, A Ferrari, G Piperno, MA Gerardi, S Comi, C Garibaldi, D Ciardo, A Bazani, F Golino, F Pansini, C Fodor, P Romanelli, D Maestri, V Scroffi, S Mazza, BA Jereczek-Fossa

29 Sep 2016

https://doi.org/10.3332/ecancer.2016.677

Abstract | Full Article | PDF

676-conditional-survival-of-metastatic-renal-cell-carcinoma-patients-treated-with-high-dose-interleukin-2

Clinical Study: Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

David M Gill, David D Stenehjem, Kinjal Parikh, Joseph Merriman, Arun Sendilnathan, Archana M Agarwal, Andrew W Hahn, Sumati Gupta, Srinivas Kiran Tantravahi, Wolfram E Samlowski, Neeraj Agarwal

29 Sep 2016

https://doi.org/10.3332/ecancer.2016.676

Abstract | Full Article | PDF